Hemorrhagic Diathesis Due to Antithrombin Pittsburgh

Hemorrhagic diathesis due to antithrombin Pittsburgh is a very rare bleeding disorder caused by a special change (mutation) in the alpha-1 antitrypsin (AAT) protein. In this mutation, one building block of the protein is swapped (methionine at position 358 is replaced by arginine). That single swap turns AAT into a very strong blocker of thrombin and other clotting enzymes. Because thrombin is needed to make a firm blood clot, blocking it makes people bleed easily or bleed for a long time after injury or surgery. Doctors first called this mutant protein “antithrombin Pittsburgh” because its behavior looks like our natural thrombin-blocker (antithrombin) and because it was discovered in Pittsburgh. The official name you will also see is alpha-1-antitrypsin Pittsburgh (A1AT-P, SERPINA1 p.Met358Arg). PMC+2PubMed+2

Antithrombin Pittsburgh” is not the usual antithrombin deficiency that causes clots. It is a special mutation of alpha-1-antitrypsin (A1AT)—a blood protein made by the liver—that changes its job. Because of a single change in the protein (methionine → arginine at position 358), the mutant A1AT behaves like a very strong inhibitor of thrombin, the enzyme that normally turns fibrinogen into fibrin to make a stable clot. When thrombin is blocked, clots do not form well, so bleeding is easy and hard to stop. This condition is sometimes called “α1-antitrypsin Pittsburgh,” “A1AT Pittsburgh,” or “antithrombin Pittsburgh” because the mutant A1AT acts like antithrombin. It is inherited (often autosomal dominant) but is extremely rare. Typical lab tests show very prolonged clotting times (PT/INR, aPTT, thrombin time). There is no heparin in the blood, but the effect can look “heparin-like” on tests. Management focuses on local hemostasis and supportive pro-coagulant therapy, and on careful planning before procedures. ASH Publications+2New England Journal of Medicine+2

Why it happens. The specific SERPINA1 gene variant called “Pittsburgh” changes A1AT’s “reactive center loop,” shifting its target from proteases like elastase to key clotting enzymes, especially thrombin (and sometimes effects on other proteases in fibrinolysis have been described). This biochemical switch explains the bleeding tendency in affected people and families reported in the literature. ASH Publications+2New England Journal of Medicine+2

This mutant AAT not only blocks thrombin; it can also strongly inhibit factor XIa and parts of the “contact system” (kallikrein, XIIf). All of that pushes the blood system toward not clotting (a bleeding tendency). PMC

---

Other names

• Alpha-1-antitrypsin Pittsburgh

• Antithrombin Pittsburgh (historic, because the mutant AAT behaves like antithrombin)

• Pi-Pittsburgh or SERPINA1 p.Met358Arg (genetic naming)

• A1AT-P (short form) PMC

---

Types

Because this is ultra-rare, there isn’t a long list of formal subtypes. Clinicians usually sort it in these simple, practical ways:

1. By genetics

   • Heterozygous (one mutated copy). This is the usual situation in reported patients. Severity can range from mild to severe, and may fluctuate with triggers. PMC

   • Homozygous (two mutated copies). Not well documented; thought to be very severe or possibly incompatible with life.

2. By clinical severity

   • Mild/triggered bleeding: bleeding appears mainly after surgery, dental work, trauma, or at ovulation (ovarian hemorrhage). haematologica.org

   • Moderate to severe: spontaneous bruises or hematomas; prolonged bleeding after minor procedures. PMC

3. By onset pattern

   • De novo (new) mutation in a child (original cases).

   • Familial (parent and child both affected), as reported in a family study. PMC

---

Causes

Here “cause” means either the root genetic cause or common triggers/co-factors that can bring out or amplify bleeding:

1. The genetic change itself: SERPINA1 p.Met358Arg converts AAT into a powerful thrombin inhibitor. This is the fundamental cause. PubMed+1

2. Contact-system inhibition (e.g., factor XIa, kallikrein) by the mutant protein further weakens clot formation. PMC

3. Surgery or invasive procedures (cuts, dental work) often unmask the problem as prolonged bleeding. haematologica.org

4. Trauma, even minor, can lead to large bruises or soft-tissue hematomas. PMC

5. Ovulation/follicle rupture in females (can cause ovarian hemorrhage/hematoma). PMC+1

6. Inflammation or infection, because AAT is an acute-phase reactant; levels rise during inflammation, so the mutant’s anti-thrombin effect can become stronger. PMC

7. Coexisting low protein C activity noted in some patients may tilt the balance variably, but in reported A1AT-P families, protein C activity can be low or absent in lab testing. PMC

8. Use of antiplatelet drugs (e.g., aspirin, many NSAIDs) adds a platelet problem on top of the clotting-enzyme block. (General hemostasis principle; clinicians avoid them in bleeding diatheses.)

9. Use of anticoagulants (e.g., heparin, warfarin, DOACs) can dramatically worsen bleeding risk. (General principle.)

10. Liver disease (makes fewer clotting factors), compounding the thrombin blockade. (General principle.)

11. Vitamin K deficiency (low factors II, VII, IX, X) worsens the tendency to bleed. (General principle.)

12. Thrombocytopenia (low platelets) from any cause. (General principle.)

13. Inherited platelet function disorders (if present) add bleeding risk. (General principle.)

14. Fibrinolytic therapy or excessive fibrinolysis (if given/occurring) can break down clots faster. (General principle.)

15. Uremia (advanced kidney failure) causing platelet dysfunction. (General principle.)

16. Alcohol excess (platelet dysfunction, liver effects). (General principle.)

17. Large vascular malformations (if present) can bleed more readily. (General principle.)

18. Uncontrolled hypertension (raises risk of internal bleeding when clots are weak). (General principle.)

19. Coagulation factor deficiencies from any other cause (e.g., severe factor XI deficiency) would add to bleeding. (General principle.)

20. Massive transfusion-related dilution of clotting factors (peri-operative) without balanced factor/platelet replacement can worsen bleeding once it starts. (General principle.)

(Notes: Items 8–20 are general hemostasis modifiers that clinicians manage carefully in any bleeding disorder; they are particularly relevant here because the core problem already weakens thrombin-driven clot formation.)

---

Common symptoms and signs

1. Easy bruising: large or frequent bruises after minimal bumps.

2. Prolonged bleeding after cuts: a small cut may ooze for a long time.

3. Post-surgical or post-dental bleeding: harder to stop than expected. haematologica.org

4. Soft-tissue hematomas: deep collections of blood in muscle or under skin, sometimes after apparently minor trauma. PMC

5. Nosebleeds (epistaxis): may be frequent or hard to control.

6. Gum bleeding with brushing or dental work.

7. Menorrhagia (heavy menstrual periods) in some females.

8. Ovarian pain or abdominal pain around ovulation if an ovarian hematoma forms; imaging may confirm it. PMC

9. Bleeding after childbirth or miscarriage procedures (triggered setting).

10. Blood in urine (hematuria) or blood in stool (GI bleeding) in some cases.

11. Prolonged bleeding after injections or blood draws.

12. Anemia (tiredness, pale skin) from repeated or hidden blood loss.

13. Swelling and pain in a limb from a deep muscle hematoma.

14. Rare serious events like intracranial bleeding (headache, confusion, weakness) if trauma occurs and clotting is very weak.

15. Family history of similar bleeding problems (in familial cases). PMC

---

Diagnostic tests

A) Physical examination (what the clinician looks for)

1. Skin and mucous membranes: look for bruises, petechiae (tiny red spots), or gum bleeding. This documents that bleeding is real and ongoing.

2. Soft-tissue/muscle tenderness or swelling: suggests a deep hematoma.

3. Abdominal/pelvic exam: in females with lower-abdomen pain, to consider ovarian bleeding; imaging usually follows. PMC

4. Signs of anemia or shock (pale skin, fast heart rate, low blood pressure) if bleeding is significant.

B) “Manual/functional” hemostasis tests (bedside or function-focused)

5. Bleeding time or platelet function screen (where available): helps rule out primary platelet problems that might coexist. (General hemostasis practice.)

6. Thromboelastography (TEG) or ROTEM: whole-blood clotting profile that can show weak clot formation and poor clot firmness when thrombin is inhibited. (General hemostasis tool.)

7. Platelet aggregometry/impedance aggregometry: to be sure platelets respond normally to agonists; thrombin-driven aggregation may look blunted in this disorder because thrombin is inhibited. PMC

8. Calibrated automated thrombography (thrombin generation assay): often shows reduced thrombin burst due to the mutant inhibitor. (Principle consistent with documented potent anti-thrombin effect.) New England Journal of Medicine

C) Laboratory and pathological tests (key for this diagnosis)

9. Prothrombin time (PT) and activated partial thromboplastin time (aPTT): often prolonged, reflecting disrupted clotting cascades when thrombin and factor XIa are inhibited. PMC+1

10. Thrombin time (TT): typically markedly prolonged because thrombin is directly blocked by the mutant AAT. PubMed

11. Reptilase time: may be normal (reptilase bypasses thrombin), helping to separate thrombin inhibition from low fibrinogen. (Standard hemostasis principle used to distinguish thrombin inhibitors.)

12. Mixing studies (1:1 with normal plasma): often show incomplete or no correction, indicating an inhibitor rather than a missing clotting factor. (General inhibitor work-up logic.)

13. Levels of clotting factors (e.g., factors X, XI, XII) and protein C activity: can appear low in plasma assays from interference/complexing; this was observed in a family with A1AT-P. PMC

14. Assays for thrombin–inhibitor complexes: can detect AAT-thrombin complexes or show reduced free thrombin. This supports the mechanism. New England Journal of Medicine

15. Alpha-1 antitrypsin level and phenotype: routine AAT levels may be normal or elevated (it’s an acute-phase protein), but the phenotype or function is abnormal. PMC

16. SERPINA1 gene testing (DNA sequencing): confirms the Met358Arg (Pittsburgh) mutation—the gold standard for diagnosis. PMC

17. Protein electrophoresis/capillary electrophoresis: may show an extra small peak near the alpha-1 region in some patients, reflecting the abnormal protein signal noted in reports. PMC

D) “Electrodiagnostic” / instrumented hemostasis analytics

1. Clot waveform analysis on coagulation analyzers: can reveal delayed clot initiation and weak clot growth when thrombin is neutralized. (General analyzer principle.)
2. Chromogenic thrombin activity assays: show reduced thrombin activity in the presence of patient plasma, consistent with a strong inhibitor. (Aligns with NEJM/JCI findings of potent antithrombin activity.) New England Journal of Medicine+1

E) Imaging tests (to locate or monitor actual bleeding)

20. Ultrasound, CT, or MRI: used to find hematomas (e.g., pelvic/ovarian, muscle) and to follow their size over time; ultrasound documented ovarian hematomas in a reported case. Endoscopy is used for GI bleeding if suspected. PMC

Non-pharmacological (non-drug) treatments

1. Direct pressure and elevation. Simple, first-line for any external bleed; hold steady pressure for longer than usual.

2. Compression bandage for muscle hematomas. Limits expansion; monitor circulation and pain.

3. Local wound care and suturing when indicated; meticulous technique to secure small vessels.

4. Topical mechanical hemostats (gelatin sponge/cellulose mesh)—act as a scaffold for clot; avoid if infected wounds.

5. Thermal cautery (nasal or surgical) to seal bleeding points.

6. Fibrin sealant/glue (topical biologic) used locally during procedures to provide a fibrin scaffold; helpful adjunct though not a systemic drug.

7. Nasal packing (absorbable or non-absorbable) for epistaxis.

8. Dental socket measures: suturing, gelatin sponge, careful post-op instructions.

9. Menstrual management without drugs: menstrual cup with measured loss tracking; iron-rich diet; gynecology planning for procedures.

10. Physiotherapy after hematoma (once safe) to restore range of motion and avoid joint stiffness.

11. Cold packs in the first 24–48 h to reduce swelling/oozing (avoid direct ice on skin).

12. Procedural planning: always alert hematology and anesthesia in advance; arrange factor support plan.

13. Medical alert identification stating the diagnosis and “avoid anticoagulants/antiplatelets.”

14. Avoidance strategy: avoid contact sports, high-risk activities.

15. Humidification and nasal care to reduce nosebleed triggers.

16. Gentle dental hygiene and regular dentist alerts to prepare local hemostasis.

17. Blood pressure control to limit re-bleeding risk.

18. Treat correctable co-factors: manage ulcers/GERD to reduce GI bleed risk.

19. Vaccinations and infection prevention (indirect): fewer severe cough/vomit episodes means fewer mucosal tears.

20. Family screening/counseling where appropriate, because this is an inherited condition. orpha.net

---

Drug treatments

Important: Doses are typical starting ranges for adults unless noted; exact plans must be individualized by a hematologist, especially in this ultra-rare disease.

1. Tranexamic acid (TXA) – Antifibrinolytic. Dose: 1 g orally 2–3×/day (or ~10 mg/kg IV every 8 h) during mucosal bleeding/procedures. Purpose: Stabilize clots at mucosal sites. Mechanism: Blocks plasminogen binding → less fibrin breakdown. Side effects: Nausea; rare thrombosis; avoid with gross hematuria (clot colic).

2. Epsilon-aminocaproic acid (EACA) – Antifibrinolytic. Dose: 4–5 g oral load then 1–1.25 g hourly (max/day varies) or IV per protocol. Purpose/Mechanism: Same class as TXA; alternative option. Side effects: Similar to TXA.

3. Fibrinogen concentrate (e.g., RiaSTAP) – Clotting factor support. Dose: per level (aim >150–200 mg/dL during bleeding). Purpose: Ensure enough fibrin precursor. Mechanism: Supplies fibrinogen for clot formation. Side effects: Thrombosis (rare), allergy.

4. Cryoprecipitate – Source of fibrinogen, vWF, factor VIII, FXIII. Dose: typically 1 unit/10 kg, recheck fibrinogen. Purpose: Boosts fibrin building blocks. Side effects: Transfusion risks.

5. 4-factor Prothrombin Complex Concentrate (PCC) – FII, VII, IX, X. Dose: 25–50 IU/kg depending on INR/clinical need. Purpose: Speed thrombin generation bypassing inhibitors. Mechanism: Supplies vitamin K–dependent factors. Side effects: Thrombosis risk.

6. Activated PCC (FEIBA) – Bypass agent. Dose: per hematology (e.g., 50–100 U/kg). Purpose: Promote thrombin generation even when inhibitors present. Side effects: Thrombosis risk.

7. Recombinant activated factor VII (rFVIIa) – Bypass agent. Dose: 90 µg/kg IV, repeat per response. Purpose: Directly triggers thrombin burst on platelet surfaces to form fibrin despite inhibitors. Side effects: Thrombosis, especially arterial.

8. Desmopressin (DDAVP) – Hemostatic adjuvant. Dose: 0.3 µg/kg IV/SC/IN before minor procedures. Purpose: Raises vWF/FVIII transiently; sometimes helps mucosal bleeding even if primary issue is thrombin inhibition. Side effects: Hyponatremia, flushing, headache.

9. Topical thrombin – Local pro-coagulant. Dose: per product, applied to surgical/dental field. Purpose: Supplies thrombin locally to overcome inhibition at the site. Side effects: Rare antibody formation.

10. Fibrin sealant (topical) – Two-component thrombin/fibrinogen glue. Dose: per surgical use. Purpose: Provides ready-made fibrin to seal bleeding surfaces. Side effects: Hypersensitivity (rare).

11. Vitamin K – Only if deficiency present. Dose: 1–10 mg oral/IV depending on cause. Purpose: Correct low vitamin K–dependent factors; not specific to Pittsburgh variant but fixes a common co-factor. Side effects: Anaphylactoid reactions (rare IV).

12. Iron therapy (oral or IV) – Treat anemia. Dose: oral 40–60 mg elemental iron daily; IV per product. Purpose: Rebuild hemoglobin after chronic loss. Side effects: GI upset (oral), infusion reactions (IV).

13. Hormonal therapy for heavy menses (combined oral contraceptives, LNG-IUS) – Gynecologic hemostasis. Dose: per gynecology. Purpose: Reduce menstrual blood loss; prevent ovulatory cyst hemorrhage. Side effects: DVT risk with estrogen, device-related effects.

14. Antifibrinolytic mouthwash (TXA solution) – Dental procedures. Dose: 5–10 mL swish and spit several times/day post-extraction. Purpose: Stabilize local clot. Side effects: Minimal if not swallowed.

15. Platelet transfusion – If thrombocytopenic or for procedural support. Dose: per count/bleeding. Purpose: Provide surface for thrombin burst; adjunctive. Side effects: Transfusion reactions.

16. Fresh frozen plasma (FFP) – Broad factor replacement. Dose: 10–15 mL/kg; re-check PT/aPTT. Purpose: General factor support; may dilute inhibitor transiently. Side effects: Volume overload, TRALI.

17. Antifibrinolytic for epistaxis (TXA nasal application) – Topical. Dose: per ENT protocol. Purpose: Shortens time to hemostasis. Side effects: Local irritation.

18. Proton pump inhibitor (PPI) – If GI bleeding risk from ulcers. Dose: per GI protocol. Purpose: Reduce acid; support mucosal healing; indirect hemostatic benefit. Side effects: Headache, rare low Mg.

19. Antibiotic stewardship – If antibiotics caused vit-K deficiency. Purpose: Limit recurrence of deficiency-related bleeding.

20. Avoidance or reversal of anticoagulants – Management principle. Purpose: Stop heparin/DOACs/warfarin if not essential; reverse per standard agents (note: protamine reverses heparin but does not neutralize the Pittsburgh inhibitor). ASH Publications

(Rationale for bypassing agents and factor/fibrinogen support comes from general inhibitor-related bleeding management and case-based experience in this ultra-rare condition. The classic literature establishes mechanism/phenotype; specific randomized trials in Pittsburgh are not feasible due to rarity.) ASH Publications+2New England Journal of Medicine+2

---

Dietary molecular supplements

1. Vitamin K (only if low): 1–2 mg/day oral food-based or prescribed dosing; function/mechanism: restores vitamin K–dependent factors (II, VII, IX, X).

2. Vitamin C: 100–200 mg/day; function: supports collagen and capillary integrity; mechanism: cofactor for collagen hydroxylation (helps fragile mucosa).

3. Iron: dose per ferritin/hemoglobin; function: rebuilds red cells; mechanism: hemoglobin synthesis.

4. Folate: 400–800 µg/day; function: RBC production; mechanism: DNA synthesis for erythropoiesis.

5. Vitamin B12: per deficiency; function: RBC production; mechanism: DNA synthesis.

6. Protein-adequate diet (not a pill): function: provides amino acids for clotting factor synthesis.

7. Copper (only if deficient): small supplemental doses; function: connective tissue strength.

8. Zinc (if low): function: wound healing.

9. Calcium and Vitamin D: function: bone and muscle support during rehab after hematomas.

10. Avoid “blood-thinning” supplements (fish oil, high-dose garlic, ginkgo, ginseng, turmeric/curcumin) unless a doctor advises—mechanism: antiplatelet/anticoagulant effects that worsen bleeding.

Note: Supplements are supportive and condition-dependent; always coordinate with your clinician.

---

Regenerative / stem-cell” drugs

There are no proven “immunity boosters,” regenerative drugs, or stem-cell therapies that treat the Pittsburgh variant today. What exists is scientific work in SERPINA1 gene therapy for classic A1AT deficiency (lung/liver disease), not for the Pittsburgh bleeding phenotype. Any such approach here would be experimental only. Below are research-oriented concepts (not recommendations):

1. AAV-based SERPINA1 gene therapy (for deficiency): conceptually increases normal A1AT; not tested for Pittsburgh bleeding.

2. Antisense/siRNA to suppress mutant allele: theoretical “allele-specific silencing” to reduce harmful mutant protein.

3. CRISPR base editing to correct p.Met358Arg in liver cells: theoretical; not in clinical use.

4. mRNA therapy to provide normal A1AT transiently: research stage; not disease-specific.

5. Hepatocyte-targeted small-molecule chaperones to alter serpin conformation: theoretical.

6. Autologous hepatocyte or stem-cell gene correction and transplantation: concept only; major risks; no clinical pathway.

Bottom line: these belong in clinical trials only, not routine care. Rare Awareness Rare Education Portal

---

Surgeries/procedures

1. Targeted surgical hemostasis (ligating a vessel, meticulous suturing) when a specific bleeding point is found.

2. Endoscopic control (GI bleeds) with clipping/coagulation, with systemic support in place.

3. Interventional radiology arterial embolization for uncontrolled bleeding where a feeding vessel can be occluded.

4. Hematoma evacuation and fasciotomy if there is compartment syndrome or neurovascular compromise.

5. Gynecologic procedures for refractory menorrhagia (e.g., endometrial ablation or hysterectomy) when childbearing is complete and all conservative options have failed.

All procedures require a hematology-approved hemostatic plan in advance.

---

Preventions

1. Carry a medical alert card/bracelet stating the diagnosis and “avoid anticoagulants/antiplatelets.”

2. Tell every clinician and dentist before procedures.

3. Avoid NSAIDs/aspirin unless specifically directed.

4. Avoid heparin and DOACs unless essential and carefully supervised.

5. Use soft toothbrush and gentle flossing; keep nasal mucosa moist.

6. Protective sports gear; avoid contact sports.

7. Control blood pressure.

8. Limit alcohol.

9. Maintain iron-adequate diet; treat anemia promptly.

10. Family counseling/testing when appropriate (inherited disorder). orpha.net

---

When to see a doctor

• Immediately (ER): head injury with headache/vomiting/confusion, large expanding hematoma, heavy uncontrolled nose/gum bleeding, black/tarry stools or vomiting blood, fainting, severe abdominal pain or swelling, new weakness/numbness.

• Urgent clinic visit: new or persistent bleeding after minor procedures, very heavy periods, recurrent nosebleeds, worsening bruising, anemia symptoms (fatigue, dizziness).

• Before any planned procedure: dental work, biopsies, surgery, pregnancies/deliveries—plan with hematology.

---

What to eat and what to avoid

Eat more of:

1. Iron-rich foods (lean red meat, liver in moderation, lentils, beans, spinach).

2. Vitamin C sources (citrus, guava, strawberries) to help iron absorption and capillary health.

3. Protein (fish, poultry, eggs, dairy, legumes) to support factor production and healing.

4. Leafy greens (natural vitamin K) in consistent amounts if you are not on vitamin-K–antagonist therapy.

5. Whole-grains, nuts (not in excess), and plenty of water to promote general health.

Avoid or limit:

1. Alcohol excess (platelet dysfunction).
2. High-dose fish oil and “blood-thinning” herbs/supplements (ginkgo, garlic, ginseng, turmeric/curcumin) unless your doctor approves.
3. NSAIDs (ibuprofen, naproxen) unless instructed otherwise.
4. Crash diets causing vitamin deficiencies.
5. Energy drinks/stimulants before procedures (can raise BP and nosebleed risk).

---

FAQs

1) Is this the same as antithrombin deficiency?
No. Antithrombin deficiency causes clotting. Antithrombin (Pittsburgh) is a mutant A1AT that over-inhibits thrombin, causing bleeding. ASH Publications

2) What exactly is mutated?
A single change in the SERPINA1 gene (Met358Arg) changes A1AT so it targets thrombin. New England Journal of Medicine

3) How rare is it?
Extremely rare; described in individual patients and small families worldwide. ASH Publications+1

4) How is it diagnosed?
By the bleeding history, prolonged PT/aPTT/thrombin time, exclusion of heparin or other anticoagulants, and genetic testing for SERPINA1 Pittsburgh. ASH Publications+1

5) Is there a cure?
No established cure. Management is supportive with local measures and pro-hemostatic therapies during bleeds or surgeries. ASH Publications

6) Will desmopressin cure it?
No. It can help mucosal bleeding in some people by raising vWF/FVIII but does not fix the thrombin inhibition.

7) Are antifibrinolytics safe?
They are commonly used for mucosal bleeding. Doctors weigh benefits vs. rare clot risks for each person.

8) Can I take aspirin or NSAIDs?
Generally avoid unless a specialist says otherwise; they worsen bleeding.

9) What about pregnancy and delivery?
Plan early with hematology/obstetrics; with a protocol, delivery can be managed safely.

10) Do I need to tell my dentist?
Yes. Dental work needs a local hemostasis plan (packing, sutures, topical agents, antifibrinolytic mouthwash).

11) Could this cause fatal bleeding?
Severe cases have been reported, so plans and precautions are important. ASH Publications

12) Is protein C always low?
No. Some reported cases had low protein C activity; others did not. PubMed

13) Is this the same as classic A1AT deficiency (lung/liver disease)?
No. That is a lack or misfolding of A1AT causing lung/liver problems. Pittsburgh changes what A1AT does, leading to bleeding. Rare Awareness Rare Education Portal

14) Does protamine reverse it like heparin?
No. This is not heparin; protamine reverses heparin only. Pittsburgh’s effect is due to mutant A1AT. ASH Publications

15) Should my family get tested?
Discuss with a genetic counselor/hematologist; it’s often autosomal dominant. orpha.net

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 13, 2025.